Clinical Trial Results

Showing: All studies [change]
Condition: Breast Cancer Location: Indiana 25 trials found
New Search
Filter
Trial Phase
Study Type
Childhood Cancer Survivor Study
N/AOBSERVATIONAL Birmingham, Alabama +4 more
RECRUITING
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
PHASE3INTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NAINTERVENTIONAL Anchorage, Alaska +4 more
RECRUITING
Daily Hand-Held Vibration Therapy
NAINTERVENTIONAL Avon, Indiana +2 more
RECRUITING
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
PHASE1INTERVENTIONAL Tucson, Arizona +4 more
RECRUITING
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
PHASE2INTERVENTIONAL Washington D.C., District of Columbia +4 more
RECRUITING
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
ATEMPT 2.0: Adjuvant T-DM1 vs TH
PHASE2INTERVENTIONAL San Francisco, California +4 more
RECRUITING
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
PHASE1INTERVENTIONAL Duarte, California +4 more
RECRUITING
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
PHASE1INTERVENTIONAL Tucson, Arizona +4 more
RECRUITING
Abatacept in Immune Checkpoint Inhibitor Myocarditis
PHASE3INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
NAINTERVENTIONAL Indianapolis, Indiana
RECRUITING
Exercise in Metastatic Breast Cancer: EMBody
NAINTERVENTIONAL New Haven, Connecticut +4 more
RECRUITING
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
PHASE2INTERVENTIONAL Scottsdale, Arizona +4 more
RECRUITING
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Galleri® in the Medicare Population.
NAINTERVENTIONAL Fort Smith, Arkansas +4 more
RECRUITING
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
PHASE2INTERVENTIONAL Atlanta, Georgia +4 more
RECRUITING
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
PHASE1, PHASE2INTERVENTIONAL Los Angeles, California +4 more
RECRUITING
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3INTERVENTIONAL Birmingham, Alabama +4 more
RECRUITING
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
PHASE1, PHASE2INTERVENTIONAL Indianapolis, Indiana +2 more
RECRUITING
Filter Trials
Trial Phase
Study Type